Diabetes is a chronic condition that has been shown to be directly related to obesity and heart-related conditions. The strain that diabetes costs put on the healthcare system are well documented. At this year's 72nd Scientific Sessions, the American Diabetes Association featured several studies that aim to help rein in diabetes costs. Here are two studies that were highlighted.
Diabetes is a chronic condition that has been shown to be directly related to obesity and heart-related conditions. The strain that diabetes costs put on the healthcare system are well documented. At this year’s 72nd Scientific Sessions, the American Diabetes Association featured several studies that aim to help rein in diabetes costs. Here are two studies that were highlighted:
Medical Expenditures Associated With Diabetes: The Change in the Last Two Decades - Zhuo et al.
Zhuo et al based this study on the fact that, although advances in anti-diabetic medications and medical technologies have substantially changed the way diabetic patients are treated, the impact of these changes on medical expenditures has not been very well documented. In order to help provide some of this data, the research team examined data from the 1987 National Medical Expenditure Survey and the Medical Expenditure Panel Survey in years 1997-98 and 2007-08 to produce nationally representative estimates of the medical utilization and expenditures attributed to diabetes in patients aged 90 years or less at 3 different times. The research team concluded that “from 1987 to 2008, the medical expenditure attributed to diabetes among persons without macrovascular complications declined in the first decade and changed little in the second decade.”
Chronic-Kidney Disease Progression and Associated Medical Costs in Type 2 Diabetes - Vupputuri et al.
Another common complication associated with type 2 diabetes is chronic kidney disease. Researchers estimated the rate of progression to chronic kidney disease and identified 25,583 members of the Kaiser Permanente Northwest and Georgia regions who had type 2 diabetes and a serum creatinine measurement in 2005. By estimating glomerylar filtration rate (GFR), Vupputuri et al assigned patients to baseline stages of kidney function and then examined all subsequent GFRs through 2010 to assess progression of kidney disease. The research team found that, “among patients who progressed to chronic kidney disease (stage 3 or greater), annual total medical costs approximately doubled after progression compared to pre-progression costs, even when dialysis costs were not included.” They also added that interventions designed to minimize progressive kidney damage would reduce the burder of chronic kidney disease in type 2 diabetes.
To read more about this study, please visit the American Diabetes Association’s website.
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
2 Commerce Drive
Cranbury, NJ 08512